🇨🇦 RKV | 🇩🇪 7JO0 | 🇺🇸 RKVTD

🇨🇦 RKV | 🇩🇪 7JO0 | 🇺🇸 RKVTD

Proven Cancer Research Experts + Revolutionary AI

Revolutionizing Cancer Drug Discovery with AI

Revolutionizing Cancer Drug Discovery with AI

Rakovina Therapeutics Inc. (🇨🇦 RKV | 🇩🇪 7JO0 | 🇺🇸 RKVTD ) is combining renowed leaders in oncology and cutting-edge AI to compress traditional drug discovery timelines and accelerate life-saving cancer treatments.

Download Investor Kit — It’s free

Learn More About Our Research

WORLD-CLASS ADVISOR- $142M TRACK RECORD

BREAKTHROUGH TECHNOLOGY - DEEP DOCKING™️ CREATOR

STRATEGIC ADVANTAGE - EXCLUSIVE AI PLATFORM RIGHTS

VALIDATED APPROACH- PROVEN COMMERCiAL SUCCESS

$500B+

invested

$500B+

invested

Massive AI Investments Reshape Healthcare

Big Pharma's Billion-Dollar Race for AI Drug Discovery

Big Pharma's Billion-Dollar Race for AI Drug Discovery

The integration of artificial intelligence into pharmaceutical R&D has sparked a race for multi-billion-dollar partnerships and massive infrastructure commitments, highlighting the major transformation happening across the industry.

RAKOVINA THERAPEUTICS INC [🇨🇦 RKV| 🇩🇪7JO0|🇺🇸RKVTD]

RAKOVINA THERAPEUTICS [🇨🇦 RKV| 🇩🇪7JO0]

RAKOVINA THERAPEUTICS INC [🇨🇦 RKV| 🇩🇪7JO0 |🇺🇸 RKVTD]

Recent AI DRUG DISCOVERY Deals

Recent AI DRUG DISCOVERY Deals

$500B U.S. AI Infrastructure Plan



OpenAI, SoftBank, Oracle joint venture "Stargate"

20 advanced AI data centers planned

Healthcare AI applications prioritized

Source:
Reuters

AstraZeneca's $5.33B China AI Deal



$110M upfront to CSPC Pharmaceutical

Up to $5.22B in milestone payments

Focus: AI-driven chronic disease solutions

Source:
Reuters

Recent Billion-Dollar AI Drug Deals



Novartis-Artios: $1.5B for PARP inhibitors

Sanofi-Remix: $1.2B for ATR inhibitors

Multiple $1B+ partnerships in DNA-damage response

Source:
Rakovina Therapeutics

The Reality:
AI is No Longer Optional

The Reality:
AI is No Longer Optional

RAKOVINA THERAPEUTICS [🇨🇦 RKV ]

These blockbuster deals are more than headlinesthey reflect the urgency with which the industry is adopting AI to dramatically reduce timelines, cost, and risk in bringing new therapies to patients.

Rakovina, with Dr. Artem Cherkasov as their Senior Scientific Advisor, leverages this same power through exclusive access to proven AI platforms (Deep Docking & Enki) that position us at the forefront of cancer innovation.

"The democratization of drug discovery requires AI-based pipelines that are orders of magnitude faster and cheaper." - Dr. Artem Cherkasov, Senior AI & Medicinal Chemistry Advisor at Rakovina Therapeutics

DR. CHERKASOV: THE AI DRUG DISCOVERY PIONEER

Why Big Pharma Trusts Dr. Artem's Technology

Why Big Pharma Trusts Dr. Artem's Technology

When the world needed COVID-19 solutions fast, Dr. Artem Cherkasov's AI platform delivered—“It took us 19 days to complete the Deep Docking of 40 billion compounds. This formerly would have taken 10 years with the fastest available technology", says Dr. Cherkasov. He's since has built the most successful AI drug discovery platform in academic history.

Creator of Deep Docking™ - the original AI engine that screened 1.3 billion compounds in under a month

$142M Roche deal - largest in University of British Columbia's history

8 successful drug candidates licensed to major pharmaceutical companies

200+ research papers, and 80+ patents filed

With Dr. Cherkasov’s visionary leadership and proprietary AI technology at our core, Rakovina is uniquely positioned to deliver the next wave of breakthrough cancer therapies.

RAKOVINA THERAPEUTICS INC [🇨🇦 RKV | 🇩🇪 7JO0 | 🇺🇸 RKVTD]

RAKOVINA THERAPEUTICS [🇨🇦 RKV|🇩🇪 7JO0]

AI VS TRADITIONAL DRUG DEVELOPMENT

The Speed Advantage of Rakovina's AI Drug Discovery

The Speed Advantage of Rakovina's AI Drug Discovery

While traditional drug development takes 4-6 years and billions of dollars to reach clinical trials, Rakovina's AI-powered approach compresses this timeline to 9-12 months—transforming thousands of potential compounds into billions of possibilities with dramatically reduced time, cost, and risk.

RAKOVINA THERAPEUTICS INC [🇨🇦 RKV | 🇩🇪 7JO0 | 🇺🇸 RKVTD]

RAKOVINA THERAPEUTICS [🇨🇦 RKV|🇩🇪 7JO0]

6X

Faster Discovery Timelines

6X

Faster Discovery Timelines

Unique Opportunity

Why Rakovina Therapeutics?

Why Rakovina Therapeutics?

RAKOVINA THERAPEUTICS INC [🇨🇦 RKV]

RAKOVINA THERAPEUTICS [🇨🇦 RKV]

Proven Blueprint

Proven Blueprint

Dr. Cherkasov's Deep Docking technology has already proven its commercial value in the real world.

First-generation success: Deep Docking identified a breakthrough compound that Roche licensed for $142M—validating the commercial potential of AI drug discovery

Second-generation advantage: Rakovina now has exclusive access to the enhanced Deep Docking 2.0 platform.

$142M

Largest deal in UBC's history

$142M

Largest deal in UBC's history

Screened billions of compounds at

100X

Screened billions of compounds at

100X

RAKOVINA THERAPEUTICS INC [🇩🇪 7JO0]

RAKOVINA THERAPEUTICS [🇩🇪 7JO0]

Exclusive AI Edge

Rakovina holds exclusive commercial rights to Dr. Cherkasov's breakthrough AI platforms for DNA-damage response drug discovery

Sole licensee of Deep Docking™ 2.0 and Enki™ platforms for DDR drug discovery

Screens billions of compounds at 100× speed, delivering 6,000× enrichment

RAKOVINA THERAPEUTICS INC [ 🇺🇸 RKVTD ]

RAKOVINA THERAPEUTICS [🇺🇸 RKVTD ]

Rapid Progression to Preclinical Development

Rakovina's AI-powered approach has generated a robust pipeline of cancer-fighting compounds, each targeting specific vulnerabilities in tumor DNA repair mechanisms.

kt-3000 series: Advanced candidate targeting aggressive cancers including breast, ovarian, and prostate tumors

kt-2000 & kt-5000 series: Next-generation compounds in development, designed for enhanced effectiveness and safety

75%

of solid tumors targeted by Rakovina's pipeline

75%

of solid tumors targeted by Rakovina's pipeline

AI predections validated in

Days

AI predections validated in

Days

RAKOVINA THERAPEUTICS INC [🇨🇦 RKV ]

RAKOVINA THERAPEUTICS [🇨🇦 RKV ]

Integrated AI-to-Lab Workflow

Integrated AI-to- Lab Workflow

Rakovina's direct access to UBC's state-of-the-art facilities allows us to immediately test AI-predicted molecules, creating a high-velocity pipeline from digital discovery to preclinical assets.

Immediate validation of AI-discovered compounds through UBC's advanced wet-lab facilities

Continuous feedback loop between AI predictions and laboratory results speeds lead development

RAKOVINA THERAPEUTICS INC [🇩🇪 7JO0]

RAKOVINA THERAPEUTICS [🇩🇪 7JO0 ]

Potential $18B Annual DDR Market by 2030

Potential $18B Annual DDR Market by 2030

The DNA-damage response market represents one of the fastest-growing opportunities in oncology.

Market validation: Recent deals like the $1.5B Artios-Novartis and $1.2B Remix-Sanofi partnerships prove the immense commercial value of DDR-targeting therapies

Competitive positioning: Rakovina's exclusive access to Dr. Cherkasov's proven AI platform—which has already generated $142M in licensing deals—positions us to capture significant market share

Download Investor Kit — It’s free

$18B

Addressable Market

$18B

Addressable Market

$18B

Addressable Market

50+

Years in cancer drug development

50+

Years in cancer drug development

RAKOVINA THERAPEUTICS INC [🇺🇸 RKVTD]

RAKOVINA THERAPEUTICS [🇺🇸 RKVTD ]

Strategic Scientific Leadership

Strategic Scientific Leadership

Rakovina's success is driven by a world-class team that combines decades of cancer research expertise with proven AI innovation. Our leadership has a track record of transforming breakthrough science into commercial success.

Artem Cherkasov, PhD: Creator of Deep Docking with 200+ research papers, 80+ patents, and 8 successful drug licenses generating over $142M in deals

Petra Hamerlik, PhD: Former AstraZeneca DDR program director with deep expertise in translating DNA-damage response research into therapeutic breakthroughs

Download Investor Kit — It’s free

NEWS

Rakovina Unveiled Preclinical Data at the AACR

Rakovina Unveiled Preclinical Data at the AACR

The World’s Premier Cancer Research Forum

Rakovina (TSX-V: RKV) was selected to present groundbreaking preclinical data at the 2025 American Association for Cancer Research (AACR) Annual Meeting, the world’s premier cancer research forum.

The company unveiled two revolutionary studies :

PARP1-Selective Inhibitors for Brain Tumors

CNS-Penetrating ATR Inhibitors

RAKOVINA THERAPEUTICS INC [🇨🇦 RKV | 🇩🇪 7JO0 | 🇺🇸 RKVTD]

RAKOVINA THERAPEUTICS [🇨🇦 RKV ]

75%

of all solid tumors with DNA damage targeted

75%

of all solid tumors with DNA damage targeted

Our Vision

A Future Without Cancer

A Future Without Cancer

Our mission is to deliver hope to patients and families by creating therapies that extend lives, improve outcomes, and redefine possibilities in cancer treatment.

RAKOVINA THERAPEUTICS INC [🇨🇦 RKV | 🇩🇪 7JO0]

RAKOVINA THERAPEUTICS [🇩🇪 7JO0 ]

Recent
Milestones

RAKOVINA THERAPEUTICS [🇩🇪 7JO0 ]

 $4.9 million

 $4.9 million

 $4.9 million

Oversubscribed private placement closed in 2025.

Partnerships with UBC, Dr. Cherkasov, and Variational AI accelerate discovery efforts.

Named among the Top Undervalued Biotech Stocks on the TSX Venture Exchange.

Ready to take part in the future of cancer health?

Ready to take part in the future of cancer health?

Download Investor Kit — It’s free

RAKOVINA THERAPEUTICS INC [🇨🇦 RKV | 🇩🇪 7JO0 | 🇺🇸 RKVTD ]

RAKOVINA THERAPEUTICS [🇺🇸 RKVTD ]